6 completed, 4 active not recruiting, 3 terminated, 2 suspended. 15 Phase 1, 8 Phase 2.
Follow Total Marrow Irradiation: new trials by email Literature Review of Total Marrow Irradiation trials Research Report on Total Marrow Irradiation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia Total Marrow Irradiation, Fludarabine (FLU), Melphalan (Mel) - Aplastic Anemia Idiopathic | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 11 | 2025-07-20 | 2025-07-22 |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 7 | 2022-07-19 | 2026-07-06 |
| BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) Conditioning regimen with half-matched (haploidentical) stem cell transplant - Acute Leukemia, MDS | Phase 2 | Recruiting | University of Illinois at Chicago | 27 | 2020-01-27 | 2026-04-06 |
| Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome Fludarabine, Laboratory Biomarker Analysis, Melphalan - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission | Phase 1 | Suspended | City of Hope Medical Center | 36 | 2018-07-06 | 2026-09-28 |
| Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim - Acute Myeloid Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 56 | 2018-03-19 | 2026-10-05 |
| Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim - Plasma Cell Leukemia in Remission, Plasma Cell Myeloma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2018-01-01 | 2017-12-13 | |
| Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes Fludarabine, Busulfan, ATG - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Active not recruiting | University of Illinois at Chicago | 38 | 2017-04-24 | 2026-10-13 |
| Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate - Adult Acute Lymphoblastic Leukemia in Complete Remission, Acute Myeloid Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 31 | 2015-06-25 | 2025-06-22 |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy - Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | Suspended | University of Chicago | 30 | 2014-12-05 | 2026-03-30 |
| Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies total marrow irradiation, fludarabine phosphate, busulfan - Acute Myeloid Leukemia, Hematologic Malignancies | Phase 1 | Completed | Case Comprehensive Cancer Center | 14 | 2014-11-05 | 2021-05-07 |
| Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML etoposide, cyclophosphamide, total marrow irradiation - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Active not recruiting | City of Hope Medical Center | 108 | 2014-05-12 | 2026-07-01 |
| TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03) Total Marrow Irradiation, Melphalan, Filgrastim (G-CSF) - Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment | Phase 1 | Completed | University of Illinois at Chicago | 12 | 2014-01-14 | 2024-11-13 |
| Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma Total Marrow Irradiation, Autologous Transplant, Melphalan - Multiple Myeloma | Phase 1 | Terminated | University of Illinois at Chicago | 3 | 2014-01-10 | 2019-10-14 |
| Total Marrow Irradiation for Refractory Acute Leukemia cyclophosphamide, cyclosporine, Fludarabine - Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 12 | 2012-08-01 | 2017-12-05 |
| Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Total marrow irradiation - Multiple Myeloma | Phase 2 | Unknown | Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice | 50 | 2012-08-01 | 2012-08-17 |
| Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma bortezomib, fludarabine phosphate, melphalan - Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p | Phase 1 | Completed | City of Hope Medical Center | 18 | 2011-03-01 | 2026-10-22 |
| Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma Total Marrow Irradiation - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Ottawa Hospital Research Institute | 27 | 2008-11-01 | 2015-07-27 |
| Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment fludarabine phosphate, melphalan, nonmyeloablative allogeneic hematopoietic stem cell transplantation - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Terminated | City of Hope Medical Center | 6 | 2008-11-01 | 2015-06-08 |
| MT2004-30: Tomotherapy for Solid Tumors filgrastim, busulfan, etoposide - Brain and Central Nervous System Tumors, Kidney Cancer | Phase 1 | Terminated | Masonic Cancer Center, University of Minnesota | 23 | 2005-08-01 | 2017-12-05 |
| Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma total marrow irradiation, melphalan, peripheral blood stem cell transplantation - Refractory Multiple Myeloma, Smoldering Multiple Myeloma | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 54 | 2004-11-01 | 2025-06-06 |
Leukemia, Myeloid, Acute (10) · Multiple Myeloma (10) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Myelodysplastic Syndromes (6) · Congenital Abnormalities (3) · Recurrence (3) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Primary Myelofibrosis (2) · Anemia, Aplastic (1) · Astrocytoma (1) · Burkitt Lymphoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1)
City of Hope Medical Center (9) · University of Illinois at Chicago (4) · Masonic Cancer Center, University of Minnesota (2) · Case Comprehensive Cancer Center (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice (1) · Ottawa Hospital Research Institute (1) · University of Chicago (1)
United States (17) · Canada (1) · China (1) · Poland (1)
Damiano Rondelli, MD (2) · Anthony S Stein (1) · Anthony Stein (1) · Firoozeh Sahebi, MD (1) · George Somlo (1) · George Somlo, MD (1) · Harold L Atkins, MD (1) · Hongtao Liu (1) · Jeffrey Y Wong (1) · John Wagner, MD (1) · Joseph Rosenthal (1) · Joseph Rosenthal, MD (1) · Michael R. Verneris, MD (1) · Molly Gallogly, MD, PhD (1) · Monzr Al Malki (1)
PMID 29065747, PMID 40534485, PMID 42150590
P30CA033572 (2), P30CA014599 (1), R01CA154491 (1)